CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 1, 2006--ImmunoGen, Inc. (Nasdaq: IMGN - News), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced that extensive data on the Company’s antibody-maytansinoid, or Tumor-Activated Prodrug (TAP), technology will be reported at the American Association for Cancer Research (AACR) meeting being held in Washington, DC, April 1-5, 2006. In addition, preclinical findings will be reported for several compounds in development by ImmunoGen and by the Company’s collaborator, the sanofi-aventis Group.
